profit from every $100 of sales.
$0$100
Nkarta
$1.48+9.63% today
-26.4% in 1 year
1-year low $1.351-year high $3.67
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nkarta sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$104 million of profit last year.
SalesProfit
Nkarta vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nkarta | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Nkarta's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -119 | -132 | -128 | -122 | |
| -116 | -126 | -119 | -113 | |
| -114 | -118 | -109 | -104 | |
| -2.61 | -2.40 | -1.60 | -1.41 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 473 | 379 | 501 | 404 |
| Cash | 37 | 31 | 28 | 40 |
| Total debt | 83 | 88 | 80 | 76 |
| Total liabilities | 101 | 106 | 93 | 92 |
| 372 | 273 | 408 | 312 | |
| 44 | 49 | 68 | 74 | |
| -20.6% | -28.8% | -20.7% | -24.8% | |
| -30.6% | -43.0% | -26.7% | -33.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -57 | -86 | -100 | -89 | |
| 47 | 28 | 4 | 1 | |
| -104 | -114 | -104 | -90 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 17 | 17 | 9 |
Valuation
- –
- –
- –
- 0.8×
- –
- –
- –
- -84.8%
- -98.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -32.2%
- -27.8%
- -30.9%
- -26.9%
- -32.9%
- –
Growth
- –
- –
- +13.6%
- –
- +22.5%
Financial health
- -0.5×
- 0.26
- 20.2%
- –
- 12.96
- 12.96
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 958
Bottom 21%of 888
Bottom 1%of 987
What analysts expect
- Average price target
- $21.60
- Range
- $15.00 – $36.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.37 | -0.39 | +5.1% |
| Mar 25, 2026 | -0.37 | -0.32 | −15.6% |
| Nov 10, 2025 | -0.29 | -0.32 | +9.4% |
| Aug 12, 2025 | -0.31 | -0.37 | +16.2% |
| May 14, 2025 | -0.43 | -0.44 | +2.3% |
| Mar 26, 2025 | -0.35 | -0.41 | +14.6% |
| Nov 7, 2024 | -0.39 | -0.37 | −5.4% |
| Aug 13, 2024 | -0.34 | -0.49 | +30.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
68Pass
Philip Fisher
33No pass
Peter Lynch
56No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
27No pass
Questions about Nkarta
Is Nkarta a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nkarta AI analysis
What does Nkarta do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. It is in Biotechnology.
Does Nkarta pay a dividend?
No. Nkarta does not pay a dividend at the moment.
Is Nkarta stock halal?
No. Nkarta does not pass our halal screen: its debt is 72% of its market value, at or above the 33% limit. How we check
How has Nkarta stock done over the past year?
Down 26.4% over the past twelve months, to $1.48. It traded between $1.35 and $3.67 and is 59.7% below its high.
Who are Nkarta's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Nkarta's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.